Clinical Trial Update: Study of Canakinumab in Patients With Myelofibrosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating canakinumab in patients with myelofibrosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia-related Myelofibrosis
• Myelofibrosis
• Myelofibrosis Post-essential Thrombocythemia
• Myelofibrosis Post-polycythemia Vera
• Polycythemia Vera-related Myelofibrosis

Drugs mentioned

• ILARIS (canakinumab)

Snippet

Sponsor: John Mascarenhas | Conditions: Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Status: RECRUITING